Subject index

Acid phosphatase
  lysosomal, 91
  as tumor marker, 112-114
Actinomycin D, 256, 257
Adrenal cancer
  neuroblastomas, 124-125, 285
  NMR imaging of, 337-338
  pheochromocytomas, 124-125, 337-338
  tumor markers in, 124-126
Adriamycin
  action of, 52-53
  in combination therapy, 54-55, 56-57, 63-65, 78
  in disseminated testicular cancer, 257, 258
  in prostatic cancer, 54-59, 63-65, 78
  as single agent, 58-59
AFP. *See* Alpha-fetoprotein (AFP)
Agar assay, double-layer soft, 94-104, 108-109
Agar gel electrophoresis, 41
Alkaline phosphatase, 130, 199
Alpha-fetoprotein (AFP)
  as surgical contraindication, 261-262
  as tumor marker, 126-128, 197, 199, 260
Aminoglutethimide, 70-71
Ammonium sulfate precipitation, 40-41
Androgen receptors
  levels in prostatic cancer, 20-28
  measurement of, 18-20, 39-45
  vs. non-receptor steroid binding proteins, 42-43
  in stromal-epithelial interactions, 28-33
  temperature effect on, 18. 43
Angiogenesis
  capillary stimulation in, 10
  defined, 1
  inhibition of, 8-11, 15
  lymphocytes in, 14
  macrophages in, 14
  mechanism of, 2-5
  techniques for studying, 14
  tumor detection based on, 5-8, 14-15
  tumor vs. normal, 15
Anti-androgens, 69-70
Antibody, as tumor marker, 119
Antigens
  blood group, 18-19
  carcinoembryonic, 120
  embryonic, 192-196
  fetal, 192-196, 291
  HLA. *See* HLA antigens
  Ia, 280, 287
  prostate, 114-115
  resistance, 281
  stage-specific, 193, 194
  tumor-associated, 195-196
Avascular phase, 1-2

Bacillus Calmette-Guerin. *See* BCG therapy
BCG therapy
  for carcinoma in situ, 177-179, 186
  vs. chemotherapy, 176-177
  clinical trials of, 170-176
  cyclophosphamide and, 175-176
  dosage in, 181-182
  historical background of, 169-170
  vs. interferon, 245
  in invasive transitional cell carcinoma, 187
  maintenance schedules for, 186
  mechanism of action of, 186-187
  mode of administration in, 181, 185-186
  oral, 174-175
  patient selection for, 172, 182
  for recurrent superficial bladder tumor, 170-177
  for residual bladder tumor, 179-181
  side effects of, 171, 175, 176-177
  toxicity of, 181-182, 185

Bladder cancer
animal models for, 246
BCG therapy for. *See* BCG therapy
carcinoma in situ, 177-179, 182, 186
HLA antigens in, 285-287, 288, 289
interferon in, 221-228, 243, 244-245, 247
invasive, 187
NMR imaging in, 343-344, 345, 346
recurrent superficial, 170-177, 221-228
residual, 178-181
tumor markers in, 118-122
Bleomycin
in disseminated testicular cancer, 256-257, 258, 263, 269
in prostatic cancer, 67-68
Blood group antigens, 18-19
Buserelin, 309

Calcitonin, 130
Capillary growth. *See* Angiogenesis
Carbohydrate metabolism, inhibition of, 90-91
Carcinoembryonic antigen (CEA), 120, 195-196
Carmustine. *See* BCNU
Cartilage, angiogenesis inhibitor in, 8-9, 14
Castration. *See* Orchiectomy, bilateral
Catecholamines, 125
CAT scans. *See* Computed axial tomographic (CAT) scans
CCNU, 62
CEA, 120
Centrifugation, 95-100
Cerebrospinal fluid, 8
Ceruloplasmin, 5
Charcoal, dextran-coated, 18, 40, 93
Chemical shift images, 358
Chemosensitivity testing
clonogenic assays, 94-104
hormone receptor assays, 93
morphologic assays, 90
with radioactive compounds, 92-93
visual indicator tests, 90-91
Chemotherapy
vs. BCG therapy, 176-177
in disseminated testicular cancer, 256-259
in prostatic cancer, 51-73, 78-84. *See also under specific agents*
in vitro testing for. *See* Chemosensitivity testing
Chlorambucil, 256
Chloroethyl-cyclohexy-nitrosourea (CCNU), 62
Cholesterol, 117, 120, 124
Chorionic gonadotropin. *See* Human chorionic gonadotropin (HCG)
Chromatography, hydrophobic, 41
Chromosomes
in bladder cancer, 121-122, 137
in renal cell carcinomas, 140
Cis-diamminedichloroplatinum. *See* Cis-platinum
Cis-platinum
action of, 54
in combination therapy, 64, 66-67
in disseminated testicular cancer, 257, 258, 268-269
in prostatic cancer, 60, 64, 66-67, 79-80
with radiation therapy, 79-80
as single agent, 60
Cloning efficiency, 102
Clonogenic assays, 94-104, 108-109
Colony counting, 101-103
Complement, 117
Computed axial tomographic (CAT) scans, 259-260, 262-263, 270
vs. NMR imaging, 322-323, 326-328, 356
Contraception, immunologic, 195, 200
Copper, in angiogenesis, 4-5
Creatine kinase-BB, 117
CT scans. *See* Computed axial tomographic (CAT) scans
Cyclophosphamide
action of, 52
with BCG therapy, 175-176
in combination therapy, 54-57, 62-67
in prostatic cancer, 54-58, 62-67, 79-80
with radiation therapy, 79-80
as single agent, 57-58
in superficial bladder cancer, 175-176
Cyproterone acetate, 69
Cystectomy, 187
Cystitis cystica, 6
Cytometry, flow, 121-122, 137

Dacarbazine. *See* Imidazole carboxamide (DTIC)
Dactinomycin. *See* Actinomycin D
Daunorubicin, 52-53
DCC, 18, 40, 93
Dehydrogenase inhibition, 91
DES. *See* Diethylstilbestrol (DES)
Dextran-coated charcoal (DCC), 18, 40, 93
DFMO, 240, 246
DHT. *See* Dihydrotestosterone (DHT)
Dialysis, 144-145, 167
Diethylstilbestrol (DES)
in combination therapy, 66, 72
vs. LHRH analogs, 307-308, 309, 311, 313, 314
α-Difluoromethylornithine (DFMO), 240, 246

Dihydrotestosterone (DHT)
binding to plasma proteins, 42
dissociation from androgen receptor, 39-40, 43
metabolization of, 41-42
Disseminated testicular cancer
chemotherapy for, 256-259
diagnosis and staging of, 259-261
early approach to, 255-256
post-chemotherapy surgical management of, 261-272, 275-276
tumor markers in, 260-261
DNA tumor markers, 121-122, 137
Doxorubicin. *See* Adriamycin
Drug incubation, 100-101
DTIC. *See* Imidazole carboxamide (DTIC)

EC, 129, 198, 206-208, 291
Electrophoresis, 41
Embryoid bodies, 192
Embryonal carcinoma (EC), 129, 198, 206-208, 291
Embryonic antigens, 192-196. *See also* Fetal antigens
stage-specific, 193, 194
tumor-associated, 195-196
Embryonic cells, 189-190, 191-192
End cells, 102, 103
Endothelial cells, in angiogenesis, 3-4, 15
Enucleation, in renal carcinoma, 147-150, 164
Epithelial cells
after centrifugation, 95-96
floater, 96
in prostatic cancer, 31-33
Epithelium, urogenital sinus (UGE), 31-32, 33
Estradiol, 116
Estramustine phosphate, 54, 59, 66-67
Estrogen therapy
androgen receptors following, 20
in combination chemotherapy, 66, 72
vs. LHRH analogs, 307-308, 309, 311, 313, 314
sex steroid binding globulin following, 20
Exclusion dye testing, 91, 103

Family studies, 282
Fetal antigens, 192-196, 291. *See also* Alpha-fetoprotein (AFP); Embryonic antigens
tumor-associated, 195-196
Fetal cells, 189-190, 191-192
Fetoprotein. *See* Alpha-fetoprotein
Fibrinogen, 120, 123
FID, 323
Flow cytometry, 121-122, 137
5-Fluorouracil (5-FU)
action of, 53
clinical trials with, 54-57
in combination therapy, 62-63, 64-65, 66-68, 78
as single agent, 57-58
Flutamide, 69-70
Folinic acid, 53-54
Follicle stimulating hormone (FSH), 311
Free inductive decay (FID), 323
FSH, 311
5-FU. *See* 5-Fluorouracil (5-FU)

Gel electrophoresis, 41
Gel filtration, 41
Genetic susceptibility, 280-281
Germ cell research, 194-196, 200
Giant cells, 102-103
Glomerulonephritis
from interferon, 230-231
NMR imaging of, 333
Glycoprotein, pregnancy specific, 129, 199

HAP, 41
Haptoglobin, 123-124
HCG. *See* Human chorionic gonadotropin (HCG)
Hemodialysis, 144-145, 167
Heparin, 3-4, 10, 15
Hexamethylmelamine, 60-62
Histocompatibility antigens. *See* HLA antigens
HLA antigens
in bladder cancer, 285-287, 288, 289
class II, 297-303
DR, 297-303
frequencies of, 282, 283
inheritance of, 280
mechanisms of disease association, 280-282
in neuroblastoma, 285
in prostatic cancer, 287-290, 302, 303
in renal cell carcinoma, 284, 302, 303
resistance from, 281
structure of, 279-280
in teratocarcinoma, 195-196
in testicular cancer, 291-293, 302, 303
tumor susceptibility from, 280-281
in Wilms' tumor, 284-285
Homovanilic acid (HVA), 125
Hormone receptor assays, 93
Hormone receptors, 115, 123. *See also* Androgen receptors
Hormones, as tumor markers, 116, 122-123, 124-126
Hormone therapy. *See* Estrogen therapy

HPL, 129
HT, 190, 192-196, 208
Human chorionic gonadotropin (HCG)
  as surgical contraindication, 261-262
  as tumor marker, 127-128, 197, 199, 200, 260
Human leucocyte antigens. *See* HLA antigens
Human placental lactogen (HPL), 129
Human teratocarcinoma (HT), 190, 192-196, 208
Human tumor stem call assay, 94-104, 108-109
HVA, 125
Hydrophobic chromatography, 41
Hydroxylapatite (HAP), 41
Hydroxyproline, 116
Hydroxyurea, 59-60, 66
Hypercalcemia, 121
Hyperplasia, atypical, 6
Hypertension, in renal carcinoma, 122

Ia antigens, 280, 287
IFN. *See* Interferon (IFN)
Imidazole carboxamide (DTIC), 55-56, 60, 61, 65-66
Immune response (Ir) genes, 280
Immunoassays, 112-113
Immunoglobulin A (IgA), 119
Immunotherapy. *See* BCG therapy; Interferon (IFN)
Interferon (IFN)
  alpha, 212
  vs. BCG therapy, 245
  beta, 212
  cell structure modification by, 240
  cell surface receptors for, 215-216
  clinical trials of, 219-221, 242-243
  composition of, 212
  cytolytic, 216
  with DEMO, 240
  dosage of, 229-231, 242
  early trials with, 211
  gamma, 212
  inhibitory effect of, 213-216, 239-240
  mechanisms of action of, 213-219, 241
  modulation of immune response by, 217-218, 241
  and NK cells, 241
  pharmacokinetics of, 218-219
  phenotype alteration by, 240
  renal clearance of, 219
  side effects of, 229-231
  standardization of, 212
  subclasses of, 211, 212, 215
  toxicity of, 229-231
  in urologic tumors, 221-229, 243, 244-247
Inversion recovery (IR), 323-324, 328-329
Ir genes, 280

17-Ketosteroids, 126
Kidney
  cancer of. *See* Renal cell carcinoma
  in interferon metabolism, 219
  NMR imaging of, 329-336, 359

Labeling index, 92-93
Lactate dehydrogenase (LDH)
  in contraception, 200
  as tumor marker, 117, 129, 260-261
Leiomyosarcoma, 338-339, 340-341
Leuprolide, 309, 312, 313
LH, 308, 311
LHRH analogs. *See* Luteinizing hormone releasing hormone (LHRH) analogs
Ligand exchange method, 26-28, 30, 43-44
Liver, NMR imaging of, 339-341
Lomustine. *See* CCNU
Luteinizing hormone (LH), 308, 311
Luteinizing hormone releasing hormone (LHRH) analogs
  clinical trials with, 309-310, 312-313
  mechanisms of action of, 308, 311-312
  sexual activity with, 313, 314
  side effects of, 309, 313, 314
  structure of, 308
Lymph node dissection, radical retroperitoneal (RPLND)
  complications following, 268-269
  indications for, 261
  operative set-up for, 264
  preoperative evaluation for, 263
  results of, 266-267
  surgical procedure for, 265
Lymphocyte adenosine deaminase, 121
Lymphocytes, in angiogenesis, 14
Lysosomal acid phosphatase, 91

Macrophages, in angiogenesis, 14
Major histocompatibility complex (MHC) antigens. *See* HLA antigens
Malignant transformation, and angiogenesis, 5-7, 14-15
Mast cells, 3-4
Melphalan, 67
Mersalyl acid, 19, 44
Mesenchyme, urogenital sinus (UGM), 29, 31-32, 33
Metanephrine, 125
Methotrexate
  in disseminated testicular cancer, 256
  in prostatic cancer, 53-54, 64-65, 67-68

Methyl-chloroethyl-cyclohexy-nitrosourea (methyl-CCNU), 60, 61, 66
Methyl-GAG, 247
MHC antigens. *See* HLA antigens
β_2-Microglobulin
  and HLA antigens, 291
  as tumor marker, 124, 130
Mithramycin, 256
Mitomycin-C, 78
Mixed lymphocyte culture (MLC), 279, 280
Monoclonal antibody, 119
Monolayer cultures, 90
Morphologic assays, 90
Murine teratocarcinoma (MT), model, 189-190, 191-192, 206-208

Natural killer (NK) cells, 241
Nephrectomy
  bilateral, 167
  extracorporeal partial, 150-154, 165-167
  radical, 143-144
  in situ partial, 147, 164
Neuroblastomas, 124-125, 285
Nitrogen mustard, 60
NK cells, 241
NMR imaging. *See* Nuclear magnetic resonance (NMR) imaging
Non-seminomatous tumors (NSGCT), 197, 199, 292, 302, 303
NP-40, 98-100
NSGCT, 197, 199, 292, 302, 303
Nuclear magnetic resonance (NMR) imaging
  of adrenal glands, 337-338
  advantages and disadvantages of, 326-327
  of bladder, 343-344, 345, 346
  chemical shift images with, 358
  contrast agents with, 352
  future capabilities of, 351-352, 358, 359-360
  history of, 317-318
  instrumentation for, 324-326
  interpretation of, 328
  of kidney and ureter, 329-336, 359
  of liver, 339-341
  with paramagnetic agents, 358, 359
  of pelvis, 341-343
  of phosphorus concentrations, 360
  physical principles of, 318-323, 355-357
  of prostate, 345-351, 359
  of retroperitoneum, 338-339, 340-341, 342
  of sodium concentrations, 360
  spectroscopy, 357-358, 360
  techniques of, 323-324, 328-329
  of testes, 359
  toxicity of, 327
  in tumor staging, 359

Orchiectomy, bilateral, 307, 309, 311, 313, 314

Papillomatosis
  with BCG therapy, 178-179
  interferon in, 221, 243, 244, 247
Paramagnetic agents, 358, 359
Parathormone, 123
Pelvis, NMR imaging of, 341-343
Pheochromocytomas, 124-125, 337-338
Phosphorus concentrations, 360
Placental alkaline phosphatase (PLAP), 199
Plating efficiency, 102
Polyclonal antibody, 119
PPD skin test, 172-173, 182, 186
Prednimustine, 59
Prednisone, 67-68
Pregnancy allosera, 193-194
Pregnancy specific beta-1 glycoprotein (SP1), 129, 199
Procarbazine, 62, 65-66
Prostaglandins, 4, 5
Prostate
  endocrine dependency of, 17
  NMR imaging of, 345-351, 359
Prostate antigens, 114-115
Prostatectomy, radical, 84
Prostatic cancer
  androgen receptor levels in, 20-28
  animal model systems for, 71-72
  bilateral orchiectomy in, 307
  chemotherapy in, 51-73, 78-84. *See also under specific agents*
  estrogen treatment of, 20-23, 307-308
  HLA antigens in, 287-290, 302, 303
  interferon in, 226, 229, 243, 246
  LHRH analogs in, 308-310, 311-314
  metastatic, 81-82
  NMR imaging of, 347-351, 359
  radiation therapy in, 57
  receptor assays in, 93
  stromal-epithelial interactions in, 28-33
  tumor kinetics in, 80-82
  tumor markers in, 112-117
Protamine sulfate
  in androgen receptor measurement, 40
  in angiogenesis inhibition, 10-11, 15
Proton imaging. *See* Nuclear magnetic resonance (NMR) imaging
Putrescine, 120

Radiation therapy, in prostatic cancer, 57, 79-80, 84
Radical retroperitoneal lymph node dissection. *See* Lymph node dissection, radical retroperitoneal (RPLND)

Radioactive compounds, in chemosensitivity testing, 92-93
Red cell adherence assay, 118
Renal autotransplantation, 153-154, 165
Renal cell carcinoma
  conservative surgery for, 145-147, 161
  etiology of, 139-140
  extracorporeal partial nephrectomy in, 150-154, 165-167
  familial, 139-140
  growth patterns of, 142-144, 161
  HLA antigens in, 284, 302, 303
  interferon in, 224-225, 228-229, 244, 245-246, 247
  NMR imaging of, 332-336, 359
  radical nephrectomy in, 143-144
  simple enucleation in, 147-150, 164
  in situ partial nephrectomy in, 147, 164
  synchronous vs. nonsynchronous bilateral, 140-142, 159-161
  treatment options for, 144-145, 161, 167
  tumor markers in, 122-124
Renal dialysis, 144-145, 167
Renal hypothermia, 147, 164
Renal transplantation, 145, 167
Renin, 122
Resistance antigens, 281
Retroperitoneum, NMR imaging of, 338-339, 340-341, 342
Rheumatoid factor, 121
RPLND. *See* Lymph node dissection, radical retroperitoneal (RPLND)

Salmon assay, 109
Saturation recovery (SR), 323
Scintillation index, 92
SE, 323-324, 328-329
Seminal vesicle invasion, 84
Seminomas
  HLA antigens in, 292-293, 302, 303
  metastasis from, 197
  tumor markers in, 126, 127, 130, 199
Semustine. *See* Methyl-CCNU
Sex steroid binding globulin (SSBG), 20-23, 42
Sialic acid, 116-117, 121, 129
Single cell suspension, 94-100
Sinus, urogenital (UGS), 32
Skin test, PPD, 172-173, 182, 186
Sodium concentrations, 360
Sodium molybdate, 19, 25-26
Soft agar assay, double-layer, 94-104, 108-109
SP1, 129, 199
Spectroscopy, 357-358, 360
Spermatogenesis, 194-195, 200
Spin echo (SE), 323-324, 328-329
SR, 323
SSBG, 20-23, 42
SSEA, 193, 194
Stage-specific embryonic antigen (SSEA), 193, 194
Stem cell assay, 94-104, 108-109
Stem cells
  in colony counting, 102, 103
  of human teratocarcinoma, 198-199, 208
Sternotomy, 261, 268
Steroid receptors, 123, *See also* Androgen receptors
Stromal-epithelial interactions, 28-33
Subtraction method, of colony counting, 102-103
Sucrose density gradient analysis, 41

TAFEA, 195-196
Temperature, and androgen receptors, 18, 43
Teratocarcinoma
  cellular differentiation in, 206-208
  and contraception, 195, 200
  embryoid body formation in, 192
  and embryonic antigens, 192-193
  embryonic-fetal cells in, 189-190, 191-192
  and germ cell research, 194-196, 200
  HLA antigens in, 291-293
  human, 190, 192-196, 208
  metastasis and recurrences in, 197-199
  murine, 189-190, 191-192, 206-208
  pregnancy allosera and, 193-194
  primary tumor in, 196-197
  staging in, 199
  tumor markers, 199-200
Testicular cancer. *See also* Disseminated testicular cancer; Seminomas; Teratocarcinoma
  familial, 293
  HLA antigens in, 291-293, 302, 303
  incidence of, 189
  NMR imaging of, 359
  nonseminomatous, 197, 199, 292, 302, 303
  tumor markers in, 126-130, 199-200
Testosterone suppression, 308-309, 311-312, 313, 314
Thiotepa, 174, 176
Thoracoabdominal incision, 261, 264
Thoracotomy, 261, 264, 268
Tomographs, whole lung, 259, 262-263. *See also* Computed axial tomographic (CAT) scans
Transferrin, 117
Transitional cell carcinoma
  angiogenesis in, 6, 7
  animal models for, 246
  BCG therapy for, 187

Transitional cell carcinoma (cont'd.)
blood group antigens in, 118, 169
HLA antigens in, 285, 288
interferon in, 221-227, 243, 244
NMR imaging of, 344, 345, 346
Transitional cells, 102, 103
Translocation and extraction procedure, 26-28
Trypan blue exclusion testing, 91, 103
T/t complex, 196
Tumor-associated fetal and embryonic antigens (TAFEA), 195-196
Tumor growth
avascular phase of, 1-2
tumor kinetics in, 80-82
vascular phase of, 2
Tumor markers
in adrenal cancer, 124-126
angiogenesis as, 5-8
in bladder cancer, 118-122
defined, 111
half-life determination for, 128
in prostatic cancer, 112-117
in renal cancer, 122-124
sensitivity of, 111, 137
specificity of, 111, 137
in testicular cancer, 126-130, 199-200, 260-261

UGE, 31-32, 33
UGM, 29, 31-32, 33
UGS, 32
Ultrasound, 259, 263
Ureter, NMR imaging of, 329-336
Urinary polyamines, 120, 124
Urinary proteins, 120-121
Urogenital sinus (UGS), 32
Urogenital sinus epithelium (UGE), 31-32, 33
Urogenital sinus mesenchyme (UGM), 29, 31-32, 33

Vanilmandelic acid (VMA), 125
Vascularization. *See* Angiogenesis
Vascular phase, 2
Vinblastine
in disseminated testicular cancer, 256-258, 269
in prostatic cancer, 53
Vincristine, 53, 60, 67-68
Visual indicator tests, 90-91
Vital staining assays, 91, 103, 109
VMA, 125
Von Hippel-Lindau syndrome, 140, 141

Whole lung tomographs (WLT), 259, 262-263
Wilms' tumor, 284-285
WLT, 259, 262-263